Sequent Scientific Limited

As of June 30, 2025, Sequent Scientific Limited trades at a trailing price-to-earnings ratio of 158.99.

As of June 30, 2025, Sequent Scientific Limited trades at an EV/EBITDA multiple of 37.48 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 37.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sequent Scientific Limited trades at an EV/FCF ratio of 124.55, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Sequent Scientific Limited maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 128.41, indicating elevated leverage, while an interest coverage ratio of 2.34 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2025. Return on capital employed (ROCE) is 10.48, useful for judging operating efficiency across full business cycles.

These figures cover the twelve months ended June 30, 2025. That works out to an effective tax rate of 29.50, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended June 30, 2025, Sequent Scientific Limited posted a gross margin of 44.66, reflecting its pricing power and cost economics. The operating margin of 7.88 and net profit margin of 1.86 provide insight into operational efficiency.

Sequent Scientific Limited's most recent stock split took place on February 25, 2016 with a 1:5 split ratio.

As of June 30, 2025, Sequent Scientific Limited has an Altman Z-Score of 7.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.